On 1 October 2025, Galapagos NV announced that its board had received non‑binding offers from consortia of financial investors for its cell‑therapy business. The announcement was made today, 2 October 2025, and marks the first public disclosure of interest in the business since the company began exploring strategic alternatives on 13 May 2025.
The board said it has opened a data room and provided confidential presentations to potential buyers and is working with the consortia to complete due diligence. A limited number of offers have been received, and the board is evaluating the terms and financing commitments of each proposal.
The deadline for bidders to submit binding, fully‑financed offers is in the coming weeks, and the board expects to announce the outcome of the review no later than 5 November 2025. The move signals that Galapagos is actively pursuing a divestiture of its cell‑therapy unit, which could unlock value for shareholders and allow the company to focus on its core oncology pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.